Autres langues Lineage Cell Therapeutics, Inc.

Actions

LCTX

US53566P1093

Temps réel estimé Cboe BZX Autres places de cotation 15:49:24 29/04/2024			Varia. 5j.	Varia. 1 janv.
1,15 ^USD	+0,88 %		+0,44 %	+5,05 %

11/03	Lineage Cell Therapeutics, Inc. annonce que les résultats précliniques sur la prise de greffe seront présentés lors de la réunion de 2024 de l'Association pour la recherche en vision et ophtalmologie.	CI
07/03	Transcript : Lineage Cell Therapeutics, Inc., Q4 2023 Earnings Call, Mar 07, 2024

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development	01/04
Lineage Cell Therapeutics : Immediate Report	24/03
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium	18/03
LINEAGE CELL THERAPEUTICS, INC. - RG6501 PHASE 1/2A CLINICAL STUDY 24 MONTH RESULTS TO BE FEATURED AT 2024 RETINAL CELL AND GENE THERAPY INNOVATION SUMMIT	14/03
RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit	13/03
RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting	11/03
Lineage Cell Therapeutics, Inc. Announces Preclinical Engraftment Results to Be Presented At 2024 Association for Research in Vision and Ophthalmology Meeting	11/03
Lineage Cell Therapeutics : FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Samuel George A. III	10/03
Lineage Cell Therapeutics : FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP- Cukkey Brian M	10/03
Lineage Cell Therapeutics : FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Howe Jill Ann	10/03
Lineage Cell Therapeutics : FORM S-3-Registration Statements	10/03
Lineage Cell Therapeutics : Annual report which provides a comprehensive overview of the company for the past year	10/03
Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q4 Revenue $8.9M, vs. Street Est of $2.8M	07/03
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	07/03
Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024	29/02
Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury	13/02
Lineage Announces FDA Clearance of IND Amendment for Opc1 Cell Transplant for the Treatment of Spinal Cord Injury	13/02
LINEAGE CELL THERAPEUTICS ANNOUNCES CLOSING OF $14.0 MILLION REGISTERED DIRECT OFFERING	12/02
Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering	09/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Lineage Cell Therapeutics, Inc.

Actions

LCTX

US53566P1093

Autres langues

Filtres